NO20041996D0 - Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI) - Google Patents

Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)

Info

Publication number
NO20041996D0
NO20041996D0 NO20041996A NO20041996A NO20041996D0 NO 20041996 D0 NO20041996 D0 NO 20041996D0 NO 20041996 A NO20041996 A NO 20041996A NO 20041996 A NO20041996 A NO 20041996A NO 20041996 D0 NO20041996 D0 NO 20041996D0
Authority
NO
Norway
Prior art keywords
tfpi
administration
treatment
tissue factor
pathway inhibitor
Prior art date
Application number
NO20041996A
Other languages
English (en)
Norwegian (no)
Inventor
Abla Abu-Zayyad Creasey
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO20041996D0 publication Critical patent/NO20041996D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20041996A 2001-10-15 2004-05-14 Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI) NO20041996D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15
PCT/US2002/032624 WO2003032904A2 (en) 2001-10-15 2002-10-15 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
NO20041996D0 true NO20041996D0 (no) 2004-05-14

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20041996A NO20041996D0 (no) 2001-10-15 2004-05-14 Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)
NO20041997A NO20041997D0 (no) 2001-10-15 2004-05-14 Behandling av sepsis ved lavdoseadministrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20041997A NO20041997D0 (no) 2001-10-15 2004-05-14 Behandling av sepsis ved lavdoseadministrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)

Country Status (17)

Country Link
US (2) US7674769B2 (https=)
EP (2) EP1446140A4 (https=)
JP (5) JP2005506345A (https=)
KR (2) KR20050036867A (https=)
CN (2) CN1604790A (https=)
AU (2) AU2002340183B2 (https=)
BR (2) BR0213293A (https=)
CA (2) CA2463738A1 (https=)
EA (2) EA200400549A1 (https=)
HU (2) HUP0500472A2 (https=)
IL (2) IL161408A0 (https=)
IS (2) IS7223A (https=)
MX (2) MXPA04003547A (https=)
NO (2) NO20041996D0 (https=)
PL (2) PL374506A1 (https=)
WO (2) WO2003055442A2 (https=)
ZA (2) ZA200403601B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1446140A4 (en) 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
WO2005019265A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
CA2605057A1 (en) * 2005-04-15 2006-10-26 Abla Creasey Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)
WO2006122139A2 (en) * 2005-05-06 2006-11-16 Novartis Ag Use of tfpi to treat severe bacterial infections
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
WO2007014199A2 (en) * 2005-07-22 2007-02-01 Novartis Ag Tfpi fragments as anti-microbial agents
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
JP2014520873A (ja) 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン ｃ−Ｆｍｓアンタゴニストの使用
BR112014011488B1 (pt) * 2011-11-15 2022-07-05 Asahi Kasei Pharma Corporation Medicamento para tratamento terapêutico e/ou melhora de sépsis
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
BR112021007460A2 (pt) 2018-10-22 2021-11-03 Asahi Kasei Pharma Corp Medicamento para tratamento terapêutico e/ou melhora de um paciente com sepse
WO2023142096A1 (en) * 2022-01-30 2023-08-03 Westlake University Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
WO1985004899A1 (en) 1984-04-19 1985-11-07 Agracetus Methods and vectors for transformation of plant cells
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5110730A (en) 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
DE69118056T2 (de) 1990-08-27 1996-10-24 Monsanto Co Anticoagulatorische Zusammensetzung aus LACI und sulfatierten Polysacchariden
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
PT643585E (pt) * 1992-06-01 2000-05-31 Chiron Corp Utilizacao de inibidor da coagulacao associado a lipoproteinas (laci) para a preparacao de um medicamento para o tratamento de inflamacao aguda ou cronica
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU4408493A (en) 1992-06-11 1994-01-04 Washington University Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
DE69635051T2 (de) 1995-06-07 2006-06-14 Chiron Corp Methode zur lösung, reinigung und rückfaltung von protein
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
ATE254472T1 (de) 1996-03-25 2003-12-15 Chemo Sero Therapeut Res Inst Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
CA2279345A1 (en) * 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
UA55448C2 (uk) 1997-04-28 2003-04-15 Елі Ліллі Енд Компані Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
WO2000030677A1 (en) 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
WO2000077254A1 (en) * 1999-06-11 2000-12-21 The Government Of The United States Of America As Represented By The Secretary, Of The Department Of Health And Human Services Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
AU5062100A (en) 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
WO2001049315A1 (en) 2000-01-06 2001-07-12 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
KR20020081330A (ko) 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2002102325A2 (en) 2001-02-28 2002-12-27 Griffin John H Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
EP1383885A4 (en) 2001-04-04 2005-11-30 American Diagnostica Inc METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EP1446140A4 (en) 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
CA2463655A1 (en) 2003-04-24
IS7224A (is) 2004-04-15
JP2006008706A (ja) 2006-01-12
WO2003055442A2 (en) 2003-07-10
PL374506A1 (en) 2005-10-31
US7674769B2 (en) 2010-03-09
IL161408A0 (en) 2004-09-27
MXPA04003548A (es) 2004-07-22
WO2003032904A2 (en) 2003-04-24
AU2002340183B2 (en) 2008-11-13
CN1604787A (zh) 2005-04-06
JP2005515214A (ja) 2005-05-26
HUP0501111A2 (en) 2007-12-28
CN1604790A (zh) 2005-04-06
BR0213292A (pt) 2006-05-23
JP2005506345A (ja) 2005-03-03
EA200400549A1 (ru) 2005-02-24
AU2002365131B2 (en) 2007-03-01
IS7223A (is) 2004-04-15
CA2463738A1 (en) 2003-07-10
ZA200403601B (en) 2006-06-28
WO2003055442A3 (en) 2004-03-04
IL161407A0 (en) 2004-09-27
JP2006008704A (ja) 2006-01-12
JP2010006839A (ja) 2010-01-14
ZA200403690B (en) 2005-03-08
NO20041997D0 (no) 2004-05-14
US20030139340A1 (en) 2003-07-24
EP1446138A2 (en) 2004-08-18
US20030139339A1 (en) 2003-07-24
HUP0500472A2 (hu) 2005-08-29
WO2003032904A3 (en) 2004-03-04
EP1446138A4 (en) 2007-03-14
BR0213293A (pt) 2004-12-21
EA200400548A1 (ru) 2005-06-30
EP1446140A4 (en) 2007-03-07
PL372138A1 (en) 2005-07-11
KR20050036867A (ko) 2005-04-20
AU2002365131A1 (en) 2003-07-15
EP1446140A2 (en) 2004-08-18
MXPA04003547A (es) 2004-07-22
KR20040040489A (ko) 2004-05-12

Similar Documents

Publication Publication Date Title
NO20041996D0 (no) Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)
ATE296619T1 (de) Feste orale dosierungsform von simethicon
NO20033594L (no) Fenetanolamin-derivater for behandling av luftveissykdommer
PT2527342E (pt) Derivados do éster cíclico uk-2a úteis para a prevenção ou tratamento de doenças fúngicas
NO20034523L (no) Pyrazolderivater for behandling av HIV
NO20031443D0 (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
NO20033373L (no) Forebyggelse av diabetes ved administrering av GnRH- antagonister
EP1461027A4 (en) TREATMENT OF NEOPLASIA
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
WO2003051838A3 (en) Protein kinase inhibitors
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
NO20003799L (no) Innkorporering av kolesterol senkende midler i konfekt- dosisformer
WO2004060261A3 (de) Verbindungen, die faktor viia-aktivtat inhieren
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
AU2001258598A1 (en) Use of metal compounds to treat gastrointestinal infections
IL159511A0 (en) Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
IL178115A0 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
NO20033809L (no) Metronomisk dosering av taxaner
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
ZA200708700B (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (TFPI)
ITTO20020166U1 (it) Dispositivo terapeutico per il trattamento di sintomi provocati da malattie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application